Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial

• Main Authors: Luca Filippi (Author), Giacomo Cavallaro (Author), Elettra Berti (Author), Letizia Padrini (Author), Gabriella Araimo (Author), Giulia Regiroli (Author), Valentina Bozzetti (Author), Chiara De Angelis (Author), Paolo Tagliabue (Author), Barbara Tomasini (Author), Giuseppe Buonocore (Author), Massimo Agosti (Author), Angela Bossi (Author), Gaetano Chirico (Author), Salvatore Aversa (Author), Roberta Pasqualetti (Author), Pina Fortunato (Author), Silvia Osnaghi (Author), Barbara Cavallotti (Author), Maurizio Vanni (Author), Giulia Borsari (Author), Simone Donati (Author), Giuseppe Nascimbeni (Author), Giancarlo la Marca (Author), Giulia Forni (Author), Silvano Milani (Author), Ivan Cortinovis (Author), Paola Bagnoli (Author), Massimo Dal Monte (Author), Anna Maria Calvani (Author), Alessandra Pugi (Author), Eduardo Villamor (Author), Gianpaolo Donzelli (Author), Fabio Mosca (Author)
• Formato: Libro
• Publicado: BMC, 2017-07-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

Abstract Background Retinopathy of prematurity (ROP) still represents one of the leading causes of visual impairment in childhood. Systemic propranolol has proven to be effective in reducing ROP progression in preterm newborns, although safety was not sufficiently guaranteed. On the contrary, topica...